Mr. Speaker, by direction of the Committee on Rules, I call up House Resolution 464 and ask for its immediate consideration. Mr. Speaker, for the purpose of debate only, I yield the customary 30 minutes to the gentleman from Texas (Mr.…
Mr. Speaker, by direction of the Committee on Rules, I call up House Resolution 464 and ask for its immediate consideration.
Mr. Speaker, for the purpose of debate only, I yield the customary 30 minutes to the gentleman from Texas (Mr. Sessions). All time yielded during consideration of the rule is for debate only.
General Leave
Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days within which to revise and extend their remarks on the resolution and to insert extraneous materials into the Record.
Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, House Resolution 464 provides for consideration of S. 5, the Stem Cell Research Enhancement Act of 2007. The closed rule provides for 1 hour of debate equally divided and controlled by the chairman and ranking minority member of the Committee on Energy and Commerce.
The rule waives all points of order against the bill and against its consideration except those arising under clause 10 of rule XXI. The rule also provides one motion to commit.
Mr. Speaker, today's debate on stem cell research should be about the hope of science. It should be about how our society has always valued ethical medical research.
Many Americans awoke this morning to a news story about a potential new stem cell research technique using skin cells from mice. It was on the front page of many newspapers precisely because our society values hope and scientific advancement when done in an ethical manner.
The bill made in order under this rule maintains that tradition. With the House's approval, expanded Federal embryonic stem cell research again will be one signature away from becoming law.
Mr. Speaker, we already know that embryonic stem cell research has a potential to cure many debilitating conditions like diabetes, Parkinson's disease, Alzheimer's, spinal cord damage, and maybe even bone marrow failure. These ailments affect the young and the old, the rich and the poor.
Families from all walks of life have had firsthand experiences with these tragedies. Sad but true, disease is one of life's great equalizers. Research and medical ingenuity are our society's tools to fight these diseases.
This shared experience, the hope that stem cell research brings, may be one reason why it enjoys such bipartisan support. Polls indicate that three out of every five Americans support stem cell research, including 54 percent of Republicans.
But there are many other reasons to endorse expanded Federal stem cell research. Earlier this year, Congress and the world heard support from an unexpected source. In testimony before Congress on March 19, the Director of the NIH made a high-profile break with the administration on shortsighted stem cell policy. He said: ``It is clear today that American science would be better served and the Nation would be better served if we let our scientists have access to more cell lines that they can study.''
The United States has always led the effort to push the frontiers of medical research. But as the NIH Director's testimony indicates, Mr. Speaker, on this issue the United States is falling behind for no good scientific or moral reason.
His testimony is in line with the consensus within the wider scientific community as well. The American Association for the Advancement of Science, the Cancer Research and Prevention Foundation, the UC Davis Medical Center in my hometown of Sacramento, the University of Texas Southwestern Medical Center at Dallas in my colleague's district, the Lance Armstrong Foundation, all of these and hundreds of others support ethical embryonic stem cell research.
Mr. Speaker, it is abundantly clear that we must update our national stem cell research policy. A bipartisan majority in Congress has tried several times. Last year, both Chambers voted by wide bipartisan margins to expand ethical Federal stem cell research. Unfortunately, the President blocked that progress, that hope, that good science. But his veto only delays the issue temporarily because support for this responsible research continues to grow.
Earlier this year, the new Democratic majority acted swiftly to reconsider the issue. The bill before us is a result of that bipartisan, bicameral leadership; and it passed by a greater margin than in the last Congress.
We should act now to forward that proposal on to the President. We should give him another chance to do what is right by signing this bill into law.
Mr. Speaker, there is little disagreement about the science of stem cell research or what ethical rules should govern it, so let's stop delaying a commonsense proposal. I urge all Members to support this rule and the underlying legislation.
Mr. Speaker, I reserve the balance of my time.
Mr. Speaker, I yield 3 minutes to the gentleman from Massachusetts (Mr. McGovern), a member of the Rules Committee.
Mr. Speaker, I want to remind everybody today that we are talking about embryonic stem cell research.
Mr. Speaker, I yield 2 minutes to the gentleman from New York (Mr. Arcuri), a member of the Rules Committee.
Mr. Speaker, before I yield, I just want to make a point that this bill sets stringent ethical guidelines for an expanded Federal embryonic stem cell research program, and it encourages new alternative sources of stem cell research, like what made the news today.
Mr. Speaker, I yield 3 minutes to the gentlewoman from Ohio, a member of the Rules Committee, Ms. Sutton.
Mr. Speaker, before I yield to the next speaker, let me just say that Mrs. Reagan was in favor of stem cell research, embryonic stem cell research. And we know that President Reagan had a very debilitating disease, and I feel that that's the reason why she has supported it.
So with that, I yield 2 minutes to the gentlewoman from Pennsylvania (Ms. Schwartz).
Mr. Speaker, I yield 2 minutes to the gentlewoman from Texas (Ms. Jackson-Lee).
(Ms. JACKSON-LEE of Texas asked and was given permission to revise and extend her remarks.)
Mr. Speaker, I yield 3\1/2\ minutes to the gentlewoman from Illinois (Ms. Schakowsky).
Mr. Speaker, I yield 2 minutes to the gentlewoman from California (Ms. Woolsey).
Mr. Speaker, I yield myself the balance of my time.
I include the following statements in support of S. 5:
Cancer Research and Prevention Foundation
Embryonic Stem Cell Research and Regenerative Medicine
June 7, 2007.
The Cancer Research and Prevention Foundation (CRPF)
strongly supports efforts to expand the current, restrictive
policy governing embryonic stem cell research, under strict,
ethical guidelines. The Stem Cell Research Enhancement Act,
S. 5, will accomplish the expansion, while maintaining strong
ethical standards. Enactment of S. 5 will provide hope to the
estimated 1.5 million men, women and children diagnosed with
cancer each year.
The House and Senate have both passed legislation in the
110th Congress that will expand the current policy by
allowing Federally-funded research to be conducted on embryos
derived after August 9, 2001, on leftover embryos that will
be otherwise destroyed or discarded by fertility clinics. The
legislation ensures that no Federal funds will be used to
create or derive embryos for research purposes, nor will any
individual be compensated for donation of an embryo for
research purposes.
According to a poll recently released by the Coalition for
the Advancement of Medical Research, nearly sixty (60)
percent of Americans want President Bush to sign the Stem
Cell Research Enhancement Act into law. More than 500 disease
advocacy organizations, universities, professional societies
and other organizations have endorsed S. 5 and the Stem cell
Research Enhancement Act.
Embryonic stem cell research may hold great potential to
improve the prevention, diagnosis and treatment of cancer.
Scientific evidence indicates that stem cells provide
powerful models of the cellular and molecular origins of many
cancer types, helping us better understand the disease and
provide insight into critical aspects of cell growth and
differentiation altered during tumorigenesis. This work may
also improve pre-clinical evaluations of drug toxicity and
efficacy, identify markers for early cancer detection and aid
in the discovery of novel treatment targets.
The Cancer Research and Prevention Foundation supports
embryonic stem cell research, as well as other forms of stem
cell research such as bone marrow stem cells, adult stem
cells and stem cells derived from cord blood.
Embryonic stem cell research has the potential to benefit
millions of Americans suffering from cancer, diabetes,
Alzheimer's, Parkinson's, spinal cord injury, heart disease
and beyond. In order to realize the full potential of
embryonic stem cell research, the Federal Government must act
quickly to ensure that research is being conducted with the
most scientifically viable stem cell lines available, that
the best and brightest medical researchers and clinicians are
involved in the field, and that the United States and top
research institutions remain leaders in biomedical and
regenerative medicine research.
Mr. Speaker, I yield back the balance of my time, and I move the previous question on the resolution.